'84 Law Angers Defense Contractors

WASHINGTON—A 1984 law to encourage competition among defense contractors has forced federal agencies to become aware of the importance of evaluating all possible bidders for contracts, but also has slowed the procurement process and angered many industry officials. The Competition in Contracting Act was an attempt by Congress to end "sweetheart" deals between the Pentagon and individual defense contractors. Its requirement that agencies seek bids from a range of contractors has led some ag

Written byDaniel Charles
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The Competition in Contracting Act was an attempt by Congress to end "sweetheart" deals between the Pentagon and individual defense contractors. Its requirement that agencies seek bids from a range of contractors has led some agencies to give out fewer, but larger, awards. Although research, including money to university-based contractors, forms only, a small portion of the Defense Department's $300 billion annual budget, it is expected to amount to $10 billion in the coming fiscal year—$3 billion for basic technology and $7 billion for advanced technology and development.

Some industry officials believe the cure has been worse than the disease. Two federal agencies, in fact, are experimenting with procedures to streamline a process that now takes almost twice as long as it did before the law was passed.

Earle Williams, president of BDM International Inc., a leading high-technology research firm, has become the R&D industry's most prominent critic of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies